Supplementary Table 1.
Clinical Characteristics of the Primary Patient Cohort
| Cohort variable | Total (n = 756)a | BF– patients (n = 604) | BF+ patients (n = 152) | P valueb |
|---|---|---|---|---|
| IBS | ||||
| Total n | 86 | 34 | 52 | |
| Sex, n (% female) | 62 (72) | 26 (76) | 37 (71) | .63 |
| Age, y, median (range) | 43 (18–76)∗∗ | 42 (19–76) | 44 (18–76) | .32 |
| IBS-C, n (%) | 7 (8) | 4 (12) | 3 (6) | .42 |
| IBS-D, n (%) | 38 (44) | 14 (41) | 24 (46) | .66 |
| IBS-M, n (%) | 41 (48) | 16 (47) | 25 (48) | 1 |
| UC | ||||
| Total n | 102 | 72 | 30 | |
| Sex (% female), n (%) | 44 (43)∗ | 31 (43) | 13 (43) | 1 |
| Age, y, median (range) | 42 (12–83)∗∗ | 39 (12–83) | 44 (17–79) | .5 |
| Endoscopic disease activity (Mayo score), median (range) | 1 (0–3) | 1 (0–3) | 0.5 (0–3) | .28 |
| Proctitis (E1), n (%), n = 98 | 17 (17) | 14 (21) | 3 (10) | .26 |
| Left-sided colitis (E2), n (%), n = 98 | 27 (28) | 22 (21) | 5 (17) | .14 |
| Pancolitis (E3), n (%), n = 98 | 54 (55) | 32 (47) | 22 (73) | .009∗∗ |
| Post-organ transplantation | ||||
| Total n | 28 | 22 | 6 | |
| Sex, n (% female) | 13 (46) | 12 (55) | 1 (17) | .17 |
| Age, y, median (range) | 61 (21–88)∗ | 62 (21–88) | 59 (55–69) | .92 |
| Liver transplant, n (%), n = 27 | 7 (26) | 4 (19) | 3 (50) | .29 |
| Heart transplant, n (%), n = 27 | 4 (15) | 3 (14) | 1 (17) | 1 |
| Kidney transplant, n (%), n = 27 | 13 (48) | 10 (48) | 3 (50) | 1 |
| Lung transplant, n (%), n = 27 | 4 (15) | 4 (19) | 0 (0) | .55 |
| Crohn’s disease | ||||
| Total n | 82 | 72 | 10 | |
| Sex, n (% female) | 35 (42)∗ | 28 (39) | 7 (70) | .09 |
| Age, y, median (range) | 40 (19–93)∗∗∗ | 40 (19–93) | 46 (26–63) | .66 |
| Endoscopic activity (SES), median (range) | 3 (0–15) | 3 (0–15) | 3 (0–15) | .87 |
| Terminal ileum (L1), n (%) | 18 (22) | 18 (25) | 0 (0) | .10 |
| Colonic (L2), n (%) | 18 (22) | 15 (21) | 3 (30) | .68 |
| Ileocolonic (L3), n (%) | 43 (52) | 36 (50) | 7 (70) | .32 |
| Upper GI (L4), n (%) | 3 (4) | 3 (4) | 0 (0) | 1 |
| Nonstricturing/nonpenetrating (B1), n (%) | 37 (45) | 33 (45) | 4 (40) | 1 |
| Stricturing/penetrating (B2/B3), n (%) | 45 (55) | 39 (55) | 6 (60) | 1 |
| Otherc | ||||
| Total n | 49 | 42 | 7 | |
| Sex, n (% female) | 22 (45) | 19 (45) | 3 (43) | 1 |
| Age, y, median (range) | 60 (22–83)∗∗ | 60 (22–83) | 59 (33–66) | .5 |
| NSAID colitis, n (%) | 2 (4) | 2 (5) | 0 (0) | 1 |
| Collagen colitis, n (%) | 2 (4) | 1 (2) | 1 (14) | .27 |
| Microscopic colitis, n (%) | 2 (4) | 2 (5) | 0 (0) | 1 |
| GI infection, n (%) | 15 (30) | 15 (36) | 0 (0) | .08 |
| Chemotherapy-induced diarrhea, n (%) | 28 (58) | 22 (52) | 6 (86) | .21 |
| Adenoma | ||||
| Total number, n | 142 | 118 | 24 | |
| Sex, n (% female) | 64 (45)∗ | 53 (45) | 11 (46) | 1 |
| Age, y, median (range) | 65 (23–91)∗∗∗ | 65 (23–91) | 66 (30–80) | .91 |
| Portal hypertension | ||||
| Total number, n | 48 | 42 | 6 | |
| Sex, n (% female) | 11 (23)∗∗∗ | 9 (21) | 2 (33) | .61 |
| Age, y, median (range) | 58 (18–83)∗ | 58 (18–83) | 53 (30–66) | .13 |
| Liver disease severity (MELD), median (range) | 15 (4–40) | 15 (4–40) | 12 (6–20) | .16 |
| Colorectal cancer | ||||
| Total n | 26 | 22 | 4 | |
| Sex, n (% female) | 16 (62) | 13 (60) | 3 (75) | 1 |
| Age, y, median (range) | 65 (35–79)∗∗∗ | 63 (35–79) | 73 (51–79) | .34 |
| Diverticular disease | ||||
| Total n | 29 | 26 | 3 | |
| Sex, n (% female) | 12 (41) | 10 (38) | 2 (67) | .55 |
| Age, y, median (range) | 67 (48–87)∗∗∗ | 67 (48–87) | 75 (60–75) | .5 |
| GI bleeding | ||||
| Total n | 52 | 50 | 2 | |
| Sex, n (% female) | 25 (48) | 24 (48) | 1 (50) | 1 |
| Age, y, median (range) | 69 (16–88)∗∗∗ | 69 (16–88) | 67 (61–73) | 1 |
| Healthy control | ||||
| Total n | 112 | 104 | 8 | |
| Sex, n (% female) | 65 (59) | 60 (58) | 5 (63) | 1 |
| Age, y, median (range) | 51 (19–81) | 52 (19–81) | 45 (22–72) | .14 |
NOTE. Values are presented as median (range) for continuous variables and n (%) for categorical variables. Percentages are calculated based on the actual number of patients in each group where the respective data were available. If data were not available for all subjects, the number of subjects for which the respective data were available is indicated in the Cohort variable column. Mann-Whitney U test and 2-sided Fisher exact test were used to determine P values for continuous and categorical variables, respectively.
IBS-C, irritable bowel syndrome with constipation predominant; IBS-D, irritable bowel syndrome with diarrhea predominant; IBS-M, irritable bowel syndrome with mixed bowel habits; MELD, Model for End-Stage Liver Disease; SES, Simple Endoscopic Score.
Column includes statistical test for age and sex difference to healthy controls, ∗P ≤ .05; ∗∗P ≤ .01.
BF+ patients vs BF– patients, ∗∗P ≤ .01.
Other represents microscopic/collagen/eosinophilic/NSAID colitis, GI infection– and chemotherapy-induced diarrhea.